TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23731437

Group type: EXPERIMENTAL
Intervention: Pictures of stimuli with different levels of fear-relevance presented with scared faces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pictures of stimuli with different levels of fear-relevance presented alone
Number of subjects: 0
Study: 21147097

Group type: EXPERIMENTAL
Intervention: Phenylephrine (3.66-8000 ng/min)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.0128-1000 ng/min)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined factors (finger temperature, BMI, age, phenylephrine sensitivity)
Number of subjects: 75
Study: 19058926

Group type: EXPERIMENTAL
Intervention: Immediate release (IR) methamphetamine (5mg, 6x/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) methamphetamine (30 mg first pill, 1x/day; 0mg 5x/day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo (0mg, 6x/day)
Number of subjects: 82
Study: 16825088

Group type: EXPERIMENTAL
Intervention: Oral vitamin E therapy (400 mg daily for 5 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: No antioxidant supplementation (Control group)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Comparison with healthy controls (N=16)
Number of subjects: 29
Study: 14961048

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (VIAGRA)
Number of subjects: 152
Study: 12881929

Group type: EXPERIMENTAL
Intervention: 0.18 g sucrose
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: 0.24 g sucrose (2 mL 12% sucrose)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Water
Number of subjects: 271
Study: 9647414

Group type: EXPERIMENTAL
Intervention: Successful late coronary angioplasty
Number of subjects: 113

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Ejection fraction >0.4
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Non-inferior myocardial infarction
Number of subjects: 113
Study: 7857509

Group type: EXPERIMENTAL
Intervention: 300 mg dried hypericum extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 900 mg dried hypericum extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 1800 mg dried hypericum extract
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3 x 300 mg/day long-term dosing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose pharmacokinetics
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Comparison of absorption lag-time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dose-response relationship
Number of subjects: 12
Study: 2685652

Group type: EXPERIMENTAL
Intervention: Sinemet CR (controlled‐release carbidopa/levodopa 50/200)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Sinemet (standard carbidopa/levodopa 25/100)
Number of subjects: 202
Study: 1203882

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide plus prednisone
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cyclophosphamide, prednisone, and chloroquine
Number of subjects: 41
Study: 30727012

Group type: COMPARATOR
Intervention: Cell saving (CS)
Number of subjects: 48
Study: 30439793

Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for hypertension
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for dyslipidemia
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Hybrid method for predicting therapeutic targets for diabetes
Number of subjects: 320
Study: 27924398

Group type: EXPERIMENTAL
Intervention: Oxabact® OC5 (O. formigenes)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26341759

Group type: EXPERIMENTAL
Intervention: Walk-and-eat intervention (n = 30; nurse-supervised walking three times per week and weekly nutritional advice)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Usual care (n = 29; control group)
Number of subjects: 59
Study: 23550171

Group type: EXPERIMENTAL
Intervention: Eclipse 3
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: EverGo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: iGo
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control walk using the subject's current oxygen system
Number of subjects: 21
Study: 21273893

Group type: COMPARATOR
Intervention: Inpatient rehabilitation (CR_In)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Inpatient rehabilitation with ambulatory training (CR_In+Amb)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CR_In declined rehabilitation)
Number of subjects: 54
Study: 19685258

Group type: EXPERIMENTAL
Intervention: Adenosine via antecubital vein at 140 microg kg(‐1) min(‐1) (A140)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine via antecubital vein at 170 microg kg(‐1) min(‐1) (A170)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Adenosine via femoral vein at 140 microg kg(‐1) min(‐1) (F140)
Number of subjects: 50
Study: 17909210

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Yoga (Viniyoga)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional restoration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superficial heat
Number of subjects: 0
Study: 15257845

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 1443

Group type: COMPARATOR
Intervention: Minimum Intervention (MI)
Number of subjects: 1443
Study: 11799305

Group type: EXPERIMENTAL
Intervention: Traditional needle placement and manipulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: New placebo device
Number of subjects: 68
Study: 9504568

Group type: EXPERIMENTAL
Intervention: Interferon-gamma (100 microg) daily by subcutaneous injection for up to 90 days
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 8070510

Group type: EXPERIMENTAL
Intervention: 60 mg naftopidil
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 29420390

Group type: EXPERIMENTAL
Intervention: Weighted Jump-Squat Training (WJST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Body Mass Squat Jump Training (BMSJT)
Number of subjects: 48
Study: 26569545

Group type: EXPERIMENTAL
Intervention: True acupuncture (TA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: True acupuncture (TA) and Sham acupuncture (SA)
Number of subjects: 17
Study: 24872875

Group type: EXPERIMENTAL
Intervention: Usual medical care
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Individualized manual therapy and rehabilitative exercise
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Community-based group exercise
Number of subjects: 180
Study: 22669400

Group type: EXPERIMENTAL
Intervention: Continuous intradermal absorbable sutures (A)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Interrupted nonabsorbable sutures (NA)
Number of subjects: 206
Study: 19943988

Group type: EXPERIMENTAL
Intervention: Radiofrequency tonsillectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Monopolar electrocautery tonsillectomy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 50
Study: 17972135

Group type: EXPERIMENTAL
Intervention: Postoperative esophageal manometry studies
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Postoperative esophageal pH studies
Number of subjects: 145
Study: 15747253

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stavudine
Number of subjects: 100
Study: 12794785

Group type: EXPERIMENTAL
Intervention: Operant pain treatment group (OTG; n = 40)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standardized medical program with emphasis on physical therapy (PTG; n = 21)
Number of subjects: 61
Study: 10808734

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 10 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (two-week treatment)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 5-mononitrate 40 mg daily for two weeks
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Propranolol (two-week therapy)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nadolol 40-80 mg daily for two weeks
Number of subjects: 168
Study: 8779382

Group type: EXPERIMENTAL
Intervention: Tunnelling of the epidural catheter subcutaneously for a distance of 5 cm
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard method of fixation with a transparent adhesive dressing
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Tunnelling of the epidural catheter
Number of subjects: 82
Study: 2005691

Group type: EXPERIMENTAL
Intervention: Intravesical BCG (50 mg weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Intravesical plus percutaneous BCG (50 mg intravesical BCG weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Number of subjects: 66
Study: 6661772

Group type: EXPERIMENTAL
Intervention: sodium‐meglumin‐joxaglat (Hexabrix)
Number of subjects: 24

Group type: COMPARATOR
Intervention: sodium‐meglumin‐diatrizoat (Urografin 76)
Number of subjects: 24
Study: 29348694

Group type: EXPERIMENTAL
Intervention: Democratic deliberation (DD) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Education group (written materials)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 27401363

Group type: EXPERIMENTAL
Intervention: PREPARE intervention (review PREPARE and an easy-to-read advance directive)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm (only the easy-to-read advance directive)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PREPARE intervention
Number of subjects: 0
Study: 24610312

Group type: EXPERIMENTAL
Intervention: St John's wort (SJW) co-administered with boceprevir
Number of subjects: 17

Group type: COMPARATOR
Intervention: Boceprevir alone
Number of subjects: 17
Study: 22460142

Group type: EXPERIMENTAL
Intervention: Tofacitinib 1 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tofacitinib 3 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 20149584

Group type: EXPERIMENTAL
Intervention: Ginger extract (120 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (1 g of coconut oil as placebo)
Number of subjects: 32
Study: 18497189

Group type: EXPERIMENTAL
Intervention: Oral health promotion program (tooth brushing 2 times/day, use of fluoridated toothpastes, dental care visits)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 9
Study: 15812606

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) in combination with placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine or placebo
Number of subjects: 30
Study: 12420344

Group type: EXPERIMENTAL
Intervention: Chitosan (750 mg pure chitosan per tablet, two tablets three times daily before each main meal)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (identical placebo tablets)
Number of subjects: 50
Study: 10624755

Group type: EXPERIMENTAL
Intervention: Tongue protrusion during posterior rhinomanometry (PRM)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tongue protrusion during PRM
Number of subjects: 32
Study: 7653757

Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg administered into the systemic circulation at 10% recovery (Group 2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Vecuronium 0.3 mg given when twitch height recovered to 50% depression (Group 3)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group with tourniquet released after 3-4 min (Group 1)
Number of subjects: 15
Study: 1952297

Group type: EXPERIMENTAL
Intervention: Pentigetide nasal solution (1 mg into each nostril four times daily)
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Pentigetide nasal solution
Number of subjects: 431

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 431
Study: 6820917

Group type: EXPERIMENTAL
Intervention: High dose of MMC immediately after operation
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Futraful for one year after MMC administration
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Futraful alone for long-term
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Futraful (dosage increase)
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: MMC and futraful combination
Number of subjects: 3030

Group type: EXPERIMENTAL
Intervention: Futraful
Number of subjects: 3030
Study: 30779395

Group type: EXPERIMENTAL
Intervention: Statin-prescribed patients
Number of subjects: 73

Group type: COMPARATOR
Intervention: Never–statin‐prescribed patients
Number of subjects: 73
Study: 29085998

Group type: EXPERIMENTAL
Intervention: Inspiratory condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Normal condition
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Expiratory condition
Number of subjects: 12
Study: 27852303

Group type: EXPERIMENTAL
Intervention: Nigella sativa
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 24817517

Group type: EXPERIMENTAL
Intervention: Preoperative breast MRI (n = 220)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Control group (no breast MRI, n = 220)
Number of subjects: 440
Study: 23153062

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrostimulation (60 minutes, wave frequency 20 Hz, pulse duration 20 us, two times a day until discharge)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (conventional rehabilitation only)
Number of subjects: 30
Study: 20601741

Group type: EXPERIMENTAL
Intervention: BCAA supplementation (isoleucine:leucine:valine = 1:2.3:1.2) at 100 mg/kg body weight
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (dextrin at 100 mg/kg body weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18945398

Group type: EXPERIMENTAL
Intervention: Mind-body skills group program (12 sessions)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 82
Study: 16355623

Group type: EXPERIMENTAL
Intervention: Toothpaste containing 2% Zanthoxylum Nitidum extract
Number of subjects: 200

Group type: COMPARATOR
Intervention: Common toothpaste (Control)
Number of subjects: 200
Study: 12648732

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10986363

Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 2

Group type: COMPARATOR
Intervention: Typically developing children
Number of subjects: 2
Study: 8960576

Group type: EXPERIMENTAL
Intervention: Flow-induced vasodilation in patients with CAD
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: L-NMMA administration
Number of subjects: 25
Study: 8251721

Group type: EXPERIMENTAL
Intervention: 100ml Naoxuenin (NXN) oral liquid with conventional treatment
Number of subjects: 42

Group type: COMPARATOR
Intervention: Current conventional treatment
Number of subjects: 42
Study: 3762902

Group type: EXPERIMENTAL
Intervention: Lysine vasopressin (0.4 ml, 23 IU per day in 3 divided doses for 15 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2 ml, 20 micrograms per day in a single dose for 15 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (administered by nasal route)
Number of subjects: 40
Study: 30714983

Group type: EXPERIMENTAL
Intervention: Yoga based mind-body intervention (MBI) with DMARDs
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (DMARDs only)
Number of subjects: 72
Study: 29087796

Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Pomegranate extract, 15 ml twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Grape seed extract, 15 ml twice a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mouthwash prepared from Guava extract, 15 ml twice a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control - Distil water, twice a day
Number of subjects: 40
Study: 27581531

Group type: EXPERIMENTAL
Intervention: Monitoring group (oral prasugrel 5 mg daily with dose or drug adjustment)
Number of subjects: 877

Group type: COMPARATOR
Intervention: Conventional group (oral prasugrel 5 mg daily with no monitoring or treatment adjustment)
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 877

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 877
Study: 25194227

Group type: EXPERIMENTAL
Intervention: Baclofen (20 and 50mg p.o.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22248751

Group type: EXPERIMENTAL
Intervention: 10% lactate clearance rate protocol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30% lactate clearance rate protocol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (6-hour EGDT strategy)
Number of subjects: 62
Study: 20034605

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted H1N1 vaccine containing 5.25 microg haemagglutinin (HA)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Non-adjuvanted H1N1 vaccine containing 21 microg HA
Number of subjects: 130

Group type: COMPARATOR
Intervention: AS03(A)-adjuvanted H1N1 vaccine
Number of subjects: 130

Group type: COMPARATOR
Intervention: Non-adjuvanted H1N1 vaccine
Number of subjects: 130
Study: 17697209

Group type: EXPERIMENTAL
Intervention: AT-1001 (12 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16123474

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 11852667

Group type: EXPERIMENTAL
Intervention: Pravastatin 10-20 mg/day for 12 weeks
Number of subjects: 21
Study: 10431553

Group type: EXPERIMENTAL
Intervention: Fasting homocysteine levels in normohomocysteinaemic individuals
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Post-methionine homocysteine levels in normohomocysteinaemic individuals
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fasting homocysteine levels variation in individuals homozygous for the 677 C‐‐>T mutation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intra-individual variability of plasma homocysteine levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Average post-methionine homocysteine levels
Number of subjects: 42
Study: 7780090

Group type: COMPARATOR
Intervention: 12 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 18 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Number of subjects: 28
Study: 11659330

Group type: EXPERIMENTAL
Intervention: Disclosure of risks and benefits of Carbamazepine
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Follow-up interviews after disclosure
Number of subjects: 39
Study: 7359305

Group type: EXPERIMENTAL
Intervention: Experimental condition (verbal aggression towards a stranger)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Experimental condition (pain tolerance procedure)
Number of subjects: 48
Study: 31995561

Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal pregnancies (control group)
Number of subjects: 24
Study: 30760581

Group type: EXPERIMENTAL
Intervention: Fevipiprant (DP2 antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study: 28381796

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine with valproic acid
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine without valproic acid
Number of subjects: 12
Study: 24787263

Group type: EXPERIMENTAL
Intervention: Parent‐Child Interaction Therapy (PCIT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 46
Study: 25073598

Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy combined with a rehabilitation program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rehabilitation program only
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Autologous PRP therapy
Number of subjects: 28
Study: 22173851

Group type: EXPERIMENTAL
Intervention: Caffeine alone (2.0 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Alcohol alone (0.6 g/kg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol/caffeine
Number of subjects: 28
Study: 20718814

Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 0
Study: 17701048

Group type: COMPARATOR
Intervention: Self-contained breathing apparatus with compressed air (BA-A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Heliox with self-contained breathing apparatus (BA-H)
Number of subjects: 12
Study: 15970291

Group type: EXPERIMENTAL
Intervention: Estradiol valerate plus dienogest
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (genistein)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All treatments (Raloxifene, Estradiol valerate plus dienogest, Soy isoflavones)
Number of subjects: 80
Study: 11920977

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 66

Group type: COMPARATOR
Intervention: Matched control sample
Number of subjects: 66